JMB-HEADER NAUKA RAS RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 51(2017) N 6 p. 782-787; DOI 10.1134/S0026893317060103 Full Text

A.A. Lushova1, M.G. Biazrova1, A.G. Prilipov2, G.K. Sadykova2, T.A. Kopylov3, A.V. Filatov1*

Next-Generation Techniques for Discovering Human Monoclonal Antibodies

1Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, 115478 Russia
2Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098 Russia
3Orekhovich Institute of Biomedical Chemistry, Moscow, 119121 Russia

*avfilat@yandex.ru
Received - 2017-04-15; Accepted - 2017-05-12

Monoclonal antibodies have found wide applications in the treatment of cancer, as well as of autoimmune, infectious, and other diseases. Several dozen new antibodies are currently undergoing different stages of clinical trials, and some of them will soon be added to the list of immunotherapeutic drugs. Most of these antibodies have been generated using hybridoma technology or a phage display. In recent years, new methods of obtaining human monoclonal antibodies have been actively developing. These methods rely on sequencing immunoglobulin genes from B lymphocytes, as well as on the creation of antibody-secreting stable B-cell lines. The term next-generation antibody-discovery platforms has already been established in the literature to refer to these approaches. Our review focuses on describing the results obtained by these methods.

human monoclonal antibodies, next-generation sequencing, B-cell immortalization, immunoglobulins



JMB-FOOTER RAS-JOURNALS